Aegon N.V. — Director's Dealing 2019

Jul 2, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Elliott Capital Advisors, L.P. (for itself and related general partners and investment managers)   Elliott International, L.P. Elliott Associates, L.P. Liverpool Limited Partnership
Company dealt in	Allergan PLC
Class of relevant security to which the dealings being disclosed relate (Note 2)	Ordinary Shares: IE00BY9D5467
Date of dealing	01/07/19

1. INTERESTS AND SHORT POSITIONS

   2. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long			Short
	Number		(%)	Number		(%)
(1) Relevant securities	100  (0.00%)
(2) Derivatives (other than options)	5,457,540 (1.66%)
(3) Options and agreements to purchase/sell	250,000 (0.076%)
Total	5,707,640 (1.741%)

1. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long			Short
	Number		(%)	Number		(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1. DEALINGS (Note 4)

   2. Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)

1. Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)
Equity Swap	Reducing long	278,238	$167.6231

1. Options transactions in respect of existing relevant securities

2. Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

1. Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

1. Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            YES/NO

Date of disclosure	02/07/19
Contact name	Michael Cross
Telephone number	0203 009 1305 mcross@elliottadvisors.co.uk
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap23

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DETAILS OF OPEN POSITIONS

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

OPEN POSITIONS (Note 1)

Product name, e.g. call option	Written, or purchased	Number of relevant securities to which the option or derivative relates	Exercise price (Note 2)	Type, e.g. American, European etc.	Expiry date
Call Option	Purchased	250,000	132 USD	American	16/08/19

Notes

1.          Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

2.          For all prices and other monetary amounts, the currency must be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.